Does Rallies show 13F holders for VRTX?

Yes. Rallies tracks hedge fund and 13F ownership data for VRTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VRTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRTX. It does not provide personalized investment advice.

VRTX (Vertex Pharmaceuticals) Stock Analysis - Hedge Fund Holdings

Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of May 20, 2026, VRTX trades at $432.75 with a market cap of $110.81B and a P/E ratio of 25.21. VRTX moved -0.91% today. Year to date, VRTX is -3.94%; over the trailing twelve months it is -1.44%. Its 52-week range spans $362.50 to $519.88. Analyst consensus is strong buy with an average price target of $565.30. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VRTX stock?

Hedge funds tracked by Rallies that own VRTX include Orbimed Advisors, Bridgewater Associates, Panagora Asset, Berkshire Asset, and Maverick Capital. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vertex Pharmaceuticals.

VRTX Key Metrics

Key financial metrics for VRTX
Metric	Value
Price	$432.75
Market Cap	$110.81B
P/E Ratio	25.21
EPS	$17.01
Dividend Yield	0.00%
52-Week High	$519.88
52-Week Low	$362.50
Volume	1.43M
Avg Volume	0
Revenue (TTM)	$12.22B
Net Income	$4.34B
Gross Margin	86.24%

Top Hedge Funds Holding VRTX

Orbimed Advisors holds 210.29K shares of VRTX, changed +31.51% as of Jun 30, 2025.
Bridgewater Associates holds 13.36K shares of VRTX, changed -51.41% as of Mar 31, 2026.
Panagora Asset holds 3.41K shares of VRTX, changed -2.21% as of Mar 31, 2026.
Berkshire Asset holds 3.15K shares of VRTX, changed -6.72% as of Mar 31, 2026.
Maverick Capital holds 812 shares of VRTX, changed +0.00% as of Dec 31, 2023.

Latest VRTX News

Vertex Pharmaceuticals Q1 EPS Hits $4.47 Despite $2.99B Revenue Miss, Barclays Sees 45% Upside — May 6, 2026
Vertex slides as Q1 revenue miss and reiterated 2026 outlook temper enthusiasm — May 5, 2026
Vertex Advances Stem-Cell Islet Therapy as BIP Wealth Adds $551,000 Stake — Apr 10, 2026
Vertex Licenses Halozyme’s Hypercon Platform for Three Targets with $15M Upfront — Apr 8, 2026
Vertex slides ~5% as traders lock in gains after March kidney-drug rally — Mar 29, 2026

Recent VRTX Insider Trades

Bhatia Sangeeta N. sold 318 (~$134.75K) on May 4, 2026.
Liu Joy sold 1.10K (~$469.22K) on May 1, 2026.
Liu Joy sold 978 (~$439.29K) on Apr 1, 2026.

VRTX Analyst Consensus

23 analysts cover VRTX: 0 strong buy, 19 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $565.30.

Common questions about VRTX

Who owns VRTX stock?: Hedge funds tracked by Rallies that own VRTX include Orbimed Advisors, Bridgewater Associates, Panagora Asset, Berkshire Asset, and Maverick Capital. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vertex Pharmaceuticals.
Does Rallies show 13F holders for VRTX?: Yes. Rallies tracks hedge fund and 13F ownership data for VRTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VRTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRTX. It does not provide personalized investment advice.